Danaher Corporation has agreed to divest assets to settle Federal Trade Commission charges that its proposed $21.4 billion acquisition of General Electric’s biopharmaceutical business, GE Biopharma, would violate federal antitrust law. The FTC alleges that the proposed acquisition would substantially lessen competition in the United States (and potentially the rest of the world) in highly […]